ELOVL7

Across TCGA pan-cancer cohorts, ELOVL7 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ELOVL7 data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ELOVL7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ELOVL7 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

PDAC, GBM, and HNSC are the cancer types where ELOVL7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.497	0.896	.007	6	view →
GBM	OS	Median	All	0.322	0.606	.040	2	view →
HNSC	OS	Median	IV	0.527	0.866	.043	2	view →
CCRCC	DFS	Tertile	All	1.000	0.706	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ELOVL7–PDAC (DFS)

Open the PDAC breakdown →